PMID- 24913499
OWN - NLM
STAT- MEDLINE
DCOM- 20160322
LR  - 20211021
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 3
DP  - 2015 Mar
TI  - Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease 
      prophylaxis after non-ablative or reduced intensity conditioning in related and 
      unrelated donor allogeneic hematopoietic cell transplant.
PG  - 663-70
LID - 10.3109/10428194.2014.930851 [doi]
AB  - Encouraging results have been reported with sirolimus, tacrolimus and low-dose 
      methotrexate after non-myeloablative allogeneic hematopoietic cell transplant. We 
      conducted a retrospective analysis of 71 patients with lymphoid malignancies 
      treated with this prophylaxis regimen after non-myeloablative or reduced 
      intensity allogeneic hematopoietic cell transplant. Grafts were human leukocyte 
      antigen (HLA)-matched related in 29 (41%), matched unrelated in 36 (51%) and 9/10 
      HLA-matched unrelated in six (8%) patients. The regimen was well tolerated and 
      over 90% of patients completed the planned treatment. The cumulative incidences 
      of 1-year grade B-D and C-D acute graft-versus-host disease (GVHD) were 0.28 (95% 
      confidence interval [CI], 0.18-0.39) and 0.07 (95% CI, 0.03-0.15), respectively, 
      and of 1- and 2-year chronic GVHD (National Institutes of Health criteria) in 70 
      evaluable patients were 0.15 (95% CI, 0.08-0.24) and 0.33 (95% CI, 0.22-0.44), 
      respectively. The median day of onset of acute GVHD was 123 days (range, 17-268 
      days). Peri-transplant rituximab or anti-thymocyte globulin did not affect GVHD. 
      The cumulative incidence of 1-year non-relapse mortality and relapse were 4% and 
      20%, respectively. With a median follow-up of 3.5 (range: 0.18-5.1) years, 
      overall survival and progression-free survival at 2 years were 82% and 66%, 
      respectively. This GVHD regimen results in a low incidence and severity of acute 
      and chronic GVHD after reduced intensity and non-myeloablative allogeneic 
      hematopoietic cell transplant for lymphoid malignancies. The study also 
      highlights the incidence of late onset acute GVHD in non-myeloablative/reduced 
      intensity conditioning, and the contribution of the new GVHD staging system that 
      more accurately reflects clinical outcomes.
FAU - Ceberio, Izaskun
AU  - Ceberio I
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center , New York, NY , USA.
FAU - Devlin, Sean M
AU  - Devlin SM
FAU - Sauter, Craig
AU  - Sauter C
FAU - Barker, Juliet N
AU  - Barker JN
FAU - Castro-Malaspina, Hugo
AU  - Castro-Malaspina H
FAU - Giralt, Sergio
AU  - Giralt S
FAU - Ponce, Doris M
AU  - Ponce DM
FAU - Lechner, Lauren
AU  - Lechner L
FAU - Maloy, Molly A
AU  - Maloy MA
FAU - Goldberg, Jenna D
AU  - Goldberg JD
FAU - Perales, Miguel-Angel
AU  - Perales MA
LA  - eng
GR  - P01 CA023766/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140806
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Immunosuppressive Agents)
RN  - W36ZG6FT64 (Sirolimus)
RN  - WM0HAQ4WNM (Tacrolimus)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
CIN - Leuk Lymphoma. 2015 Mar;56(3):555-6. PMID: 25065702
MH  - Adult
MH  - Aged
MH  - Female
MH  - Graft vs Host Disease/*prevention & control
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Methotrexate/*therapeutic use
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sirolimus/*therapeutic use
MH  - Tacrolimus/*therapeutic use
MH  - Transplantation Conditioning/*methods
MH  - Transplantation, Homologous/methods
MH  - *Unrelated Donors
MH  - Young Adult
PMC - PMC4379042
MID - NIHMS669931
OTO - NOTNLM
OT  - Sirolimus
OT  - graft-versus-host disease
OT  - non-myeloablative conditioning
OT  - reduced intensity
COIS- CONFLICT OF INTEREST: The authors declare no conflict of interest.
EDAT- 2014/06/11 06:00
MHDA- 2016/03/24 06:00
PMCR- 2016/03/01
CRDT- 2014/06/11 06:00
PHST- 2014/06/11 06:00 [entrez]
PHST- 2014/06/11 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - 10.3109/10428194.2014.930851 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015 Mar;56(3):663-70. doi: 10.3109/10428194.2014.930851. Epub 
      2014 Aug 6.